Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Amgen speaks out about bone density concerns with obesity drug
Amgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data spreadsheet.
Amgen defends obesity drug amid bone concerns
After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and has asked the journal to issue a correction and add in the finalized data.
Amgen dismisses bone density concerns related to its weight-loss drug
Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after those concerns wiped off more than $12 billion from the company's market value.
Amgen stock falls as analysts mull over weight loss drug's bone density data
Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone mineral density over 12 weeks.
Amgen Says No Link Between MariTide And Changes In Bone Mineral Density
Wednesday said there is no association between administration of experimental weight loss drug MariTide and changes
1d
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density
Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone ...
1d
What’s Happening With Amgen Stock?
In this photo illustration, Amgen logo is displayed on a smartphone with a S&P ... [+] index website background. (Photo ...
STAT
2d
A scrap of data on Amgen’s obesity drug candidate wipes out $12 billion in market value
a tiny shred of data on
Amgen
’s lead obesity candidate — not yet verified — erased $12 billion in market value. The data, ...
pharmaphorum
1d
Amgen plays down safety concern with obesity candidate
Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone ...
FierceBiotech
1d
Hidden data on obesity prospect wipe $12B off Amgen market cap
The tab contains data on bone density changes in patients who received
Amgen
’s obesity prospect
MariTide
in a phase 1 ...
MarketWatch
1d
Amgen Says No Link Between MariTide, Bone Density Loss
Amgen
on Wednesday sought to allay concerns that its
MariTide
, investigational weight-loss shot could be linked to a loss of bone mineral density.
Amgen
shares fell more than 7% on Tuesday after ...
Hosted on MSN
1d
Amgen dismisses bone density concerns related to its new weight-loss drug
The company's stock slumped 7% on Tuesday after analysts at Cantor Fitzgerald said their review of early-stage data on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback